These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16142366)

  • 1. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
    He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
    Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
    He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
    Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
    Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
    PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
    He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
    Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
    Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
    BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
    Jagarlamudi KK; Shaw M
    Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma.
    Sharif H; von Euler H; Westberg S; He E; Wang L; Eriksson S
    Vet J; 2012 Oct; 194(1):40-7. PubMed ID: 22516918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thymidine kinase 1 activity in breast cancer.
    Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
    Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
    He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
    Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
    Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
    Li HX; Lei DS; Wang XQ; Skog S; He Q
    Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.
    Bolayirli M; Papila C; Korkmaz GG; Papila B; Aydoğan F; Karataş A; Uzun H
    J Clin Lab Anal; 2013 May; 27(3):220-6. PubMed ID: 23686779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
    Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
    J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.
    Wang L; Sharif H; Saellström S; Rönnberg H; Eriksson S
    BMC Vet Res; 2021 Sep; 17(1):316. PubMed ID: 34579716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
    Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
    Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can thymidine kinase levels in breast tumors predict disease recurrence?
    O'Neill KL; Hoper M; Odling-Smee GW
    J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thymidine kinase 1 protein concentrations and presence of its autoantibody as biomarkers for screening dogs with malignant tumors.
    Kim Y; Park J; Kim B; Yu KR; Kim HS; Oh Y; Seo K; Ryu M; Park C; Bhang D; Choi U; Youn H
    J Vet Intern Med; 2024; 38(1):300-307. PubMed ID: 38088206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.